Abstract Number: 2439 • ACR/ARHP Annual Meeting 2017
Switching from RA Originator to Biosimilar in Routine Clinical Care: Early Data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Background/Purpose: Biosimilars, biopharmaceuticals assessed by regulatory agencies to have efficacy and safety similar to their reference products, were introduced to the UK market in February…Abstract Number: 1999 • ACR/ARHP Annual Meeting 2016
Claims-Based Analysis of Cost-Effectiveness Among Patients with Rheumatoid Arthritis Who Switched from a Tumor Necrosis Factor Inhibitor to Another Targeted Disease-Modifying Antirheumatic Drug
Background/Purpose: Patients with rheumatoid arthritis (RA) who have an inadequate response to a tumor necrosis factor inhibitor (TNFi) can switch to another targeted disease-modifying antirheumatic…Abstract Number: 617 • ACR/ARHP Annual Meeting 2015
Biological Down-Titration in RA: Patient Profile and Response to Retreatment in Flaring Patients
Background/Purpose: Down-titration of biological therapy (BT) in rheumatoid arthritis (RA) patients with a good clinical response is frequently applied in daily clinical practice. An important…Abstract Number: 1166 • ACR/ARHP Annual Meeting 2014
5 Year Budget Impact Analysis of Biosimilar Infliximab for the Treatment of Rheumatoid Arthritis in UK, Italy, France and Germany
Background/Purpose: Biosimilar infliximab has been approved by EMA based on comparable quality, safety and efficacy profile to infliximab for the management of inflammatory autoimmune disorders…Abstract Number: 481 • ACR/ARHP Annual Meeting 2013
Down-Titration of Biological Therapies In Rheumatoid Arthritis In Daily Clinical Practice
Background/Purpose: One of the limiting factors for the use of biological therapies (BT) is cost. For this reason, the development of cost optimization strategies without…
ACR Meeting Abstracts